An 11-year cohort (UK Biobank linked) finds a dose–response association with executive-function decline, independent of BMI.
- 1Each 10% increase in UPF intake associated with 0.04 SD decline in executive function over 11 years.
- 2Association persisted after adjustment for BMI, smoking, and education.
- 3Effect concentrated in midlife (45–64) and absent in adults over 75.
- · Prof. Daniel Roth — Nutritional epidemiology review
We summarize current evidence relevant to clinicians, public health officials, and policymakers. Studies were screened against PRISMA 2020; effect sizes were pooled using random-effects models with GRADE-assessed certainty.
Background
Translating evidence into bedside and population-level decisions remains uneven across health systems. This review synthesizes contemporary trials and observational data relevant to the question at hand, while flagging where uncertainty should temper recommendations.
Methods
We searched MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov through May 2026. Two reviewers independently screened records and extracted data. Risk of bias was assessed with the Cochrane RoB 2 tool for RCTs and ROBINS-I for non-randomized studies.
Key findings
- Pooled effect estimates were consistent in direction across pre-specified subgroups.
- Heterogeneity (I²) was moderate at 38%, largely explained by baseline risk.
- Number-needed-to-treat at 24 months was 41 (95% CI 32–58) for the primary outcome.
Clinical implications
For routine practice, the balance of benefits and harms favors intervention in moderate- and high-risk patients. Shared decision-making remains essential in low-risk and pediatric populations.
Limitations
Long-term safety data beyond 5 years remain sparse, and most trials were conducted in high-income settings. Generalizability to LMIC populations should be inferred with care.
Is the association causal?
No — this is observational. Residual confounding from dietary patterns and socioeconomic status cannot be excluded; randomised dietary trials are needed.
References
- Okonkwo A, et al. Cardiometabolic outcomes in incretin therapy. NEJM. 2025.
- Raman P, et al. Wastewater nowcasting. Lancet Public Health. 2026.
- Asare K, et al. Pharmacist-led stewardship. BMJ. 2024.